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SUMMARY 46 
'Heteroresistance' describes a phenomenon where subpopulations of seemingly isogenic bacteria 47 
exhibit a range of susceptibilities to a particular antibiotic. Unfortunately, lack of standard 48 
methods to determine heteroresistance has led to inappropriate use of this term. Heteroresistance 49 
has been recognized since at least 1947 and occurs in Gram-positive and Gram-negative 50 
bacteria. Its clinical relevance could be considerable, since more resistant subpopulations may be 51 
selected during antimicrobial therapy. However, using non-standard methods to define 52 
heteroresistance, which are costly and involve considerable labor and resources, precludes 53 
evaluating the clinical magnitude and severity of this phenomenon. We review the available 54 
literature on antibiotic heteroresistance and propose recommendations for definitions and 55 
determination criteria for heteroresistant bacteria. This will help assessing the global clinical 56 
impact of heteroresistance and developing uniform guidelines for improved therapeutic 57 
outcomes. 58 
 59 
INTRODUCTION 60 
Infections by multidrug-resistant bacteria impose a serious encumbrance worldwide on society 61 
and economy and account for increasing global morbidity and mortality (1). Variable responses 62 
to antibiotics from bacterial cells within the same population, known as heteroresistance, is a 63 
poorly characterized phenomenon that further complicates the study of antibiotic resistance and 64 
its clinical relevance is uncertain. Heterogeneous antibiotic resistance was first described in 1947 65 
for the Gram-negative bacterium Haemophilus influenzae (2), and almost 20 years later for 66 
Gram-positive staphylococci (3), but the first reported use of the term ‘heteroresistance’ occurred 67 
in 1970 (4). Heterogeneous resistance, population-wide variation of resistance, and heterogeneity 68 
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of response to antibiotics are also used to describe this phenomenon. The Clinical and 69 
Laboratory Standards Institute (CLSI), the British Society of Antimicrobial Chemotherapy 70 
(BSAC), and other international bodies develop clinical laboratory standards and 71 
recommendations for practices concerning antimicrobial resistance (5). Therefore, antimicrobial 72 
susceptibility testing methods such as MIC and disc-diffusion techniques, and standard criteria to 73 
define isolates as susceptible, resistant or intermediately resistant to any antibiotic are generally 74 
agreed upon worldwide. In contrast, heteroresistance is poorly characterized and consensus-75 
based standards to define it are lacking. 76 
In the literature, the term ‘heteroresistance’ has been indiscriminately applied to describe not 77 
only population-wide variation in antibiotic resistance but also other observations, and methods 78 
to determine heteroresistance vary significantly among laboratories. Confusion regarding this 79 
phenomenon precludes establishing its clinical significance and implementing proper therapeutic 80 
interventions and guidelines. Therefore in this review, we critically assess the published 81 
literature on heteroresistance, expose contradictions and variations in its definition, and 82 
recommend an operational definition and uniform criteria to assess heteroresistant bacteria. 83 
 84 
MULTIPLE DEFINITIONS OF HETERORESISTANCE 85 
Heteroresistance means population-wide, variable response to antibiotics (6). Several reports 86 
including the earliest studies describing the phenomenon applied this definition without 87 
specifying a particular antibiotic concentration range (3, 4, 7, 8). In contrast, concentration 88 
ranges were indicated for heteroresistance in Acinetobacter baumannii where subpopulations 89 
grew in 3 to 10 µg/ml colistin while the culture's MIC ranged from 0.25 to 2 µg/ml (9). Others 90 
described heteroresistance when a subset of the microbial population was resistant to an 91 
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antibiotic while the rest of the population was susceptible based on the concentration breakpoints 92 
of traditional in vitro susceptibility testing (10). This definition excludes cases where the 93 
bacterial culture comprises subpopulations with varying levels of resistance, but the entire 94 
population is either sensitive (Fig. 1D) or resistant (Fig. 1F) to the antibiotic. 95 
Other definitions of heteroresistance contributed to the misconception about the nature of the 96 
phenomenon. Some of them were based on single cut-off concentrations, which did not describe 97 
the variation in resistance among members of a bacterial population. For example, 98 
heteroresistance was defined by growth of A. baumannii colonies on plates containing 8 µg/ml of 99 
colistin, with confirmation of MIC of 8 µg/ml by subsequent broth microdilution method (11). 100 
Similarly, heterogeneously resistant staphylococci were defined as any culture containing 101 
subpopulations at a frequency of 1 in 106 CFU/ml or higher with MIC > 4 µg/ml for vancomycin 102 
or ≥ 16 µg/ml for teicoplanin (12) or simply with MIC above these specified in CLSI guidelines 103 
for breakpoints of vancomycin or teicoplanin (13). A similar definition was adopted by setting a 104 
cut-off diameter of 10 mm in disc diffusion assays below which the strain was considered 105 
heteroresistant rather than merely resistant (14). Another approach defined heteroresistance as 106 
high MIC of Enterococcus faecium against vancomycin (>256 µg/ml) by broth dilution, but low 107 
MIC (=1.8 µg/ml) by Etest (15). 108 
Other forms of heterogeneous bacterial behaviour against antibiotics were reported as 109 
heteroresistance. Certain S. aureus strains displayed methicillin resistance at high antibiotic 110 
concentrations (64 to 512 µg/ml) and susceptibility at low concentrations (2 to 16 µg/ml) (16). 111 
This phenomenon, termed "Eagle-type" resistance, was similar to the Eagle killing by penicillin 112 
described earlier, in which the bactericidal action of penicillin paradoxically decreased at high 113 
antibiotic concentrations (17). Similar patterns of bimodal growth in population analysis profiles 114 
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were observed in A. baumannii with cefepime, where growth inhibition after an initial peak of 115 
growth at low antibiotic concentration was followed by another peak of growth at higher 116 
concentration (18). Certain S. aureus strains displayed 'thermosensitive' heteroresistance where 117 
cultures growing in high methicillin concentrations at 30°C lost this ability within 30 minutes 118 
after shifting the growth temperature to 37°C (19). A temperature shift in the reverse direction 119 
caused equally rapid expression of methicillin resistance (19). 120 
Adding to the confusion, 'heteroresistance' was applied to describe infections with bacterial 121 
strains having different levels of resistance to an antibiotic. Amoxicillin-resistant and -122 
susceptible Helicobacter pylori isolates (MICs of 2 µg/ml and 0.06 µg/ml, respectively) were 123 
observed in different biopsies from one patient, a case described as 'inter-niche' heteroresistance 124 
(20). More recently, pairs of H. pylori isolated from the same patients had different levels of 125 
resistance to levofloxacin, metronidazole and in only one case to clarithromycin; the antibiotic 126 
resistant strains were mostly derived from a pre-existing sensitive strain rather than from 127 
infection with different strains of H. pylori having different levels of antibiotic resistance (21). 128 
Similarly, heteroresistance in Mycobacterium tuberculosis was defined as coexistence of anti-129 
tuberculosis drug-susceptible and -resistant bacteria in the same patient (22, 23). More recently, 130 
heteroresistance in M. tuberculosis was redefined as coexistence of populations with different 131 
mutations in a drug resistance locus within a sample of organisms (24). Therefore, 132 
heteroresistance does not have a uniformly consistent definition, making retrospective 133 
comparisons to assess its true clinical significance impossible. 134 
 135 
MEASURING HETERORESISTANCE 136 
 137 
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Population analysis profiling (PAP) 138 
The PAP method is considered the gold standard for determining heteroresistance. In this 139 
method, the bacterial population is subjected to a gradient of antibiotic concentrations (either on 140 
plates or in liquid medium) and bacterial growth at each of these concentrations is quantified. 141 
The PAP is typically performed using the format of standard MIC determination with 2-fold 142 
antibiotic increments and by spread-plate techniques for CFU counting (3, 4, 6, 8, 14, 16, 18, 19, 143 
25-41). Counting CFU by dropping smaller aliquots was as efficient as spread-plate (6, 42). 144 
Turbidimetric PAP assays are also performed using 2-fold antibiotic increments (6, 43), and 145 
antibiotic increments wider than 2-fold steps (2, 44).  146 
 Recently, heteroresistance was considered if the antibiotic concentration exhibiting the 147 
highest inhibitory effects was at least 8-fold higher than the highest non-inhibitory concentration 148 
(6), which allows comparisons of the isolate's behaviour against different antibiotics. However, 149 
most studies lacked criteria to define homogeneous vs. heterogeneous resistance. Lack of a 150 
standardized method to perform PAP, in particular the selection of antibiotic concentration 151 
increments led to confounding observations. For example, several studies investigated the 152 
response to glycopeptide antibiotics using PAP assays with narrow increments in antibiotic 153 
concentrations, such as 1 µg/ml steps (9, 13, 45-65) and even as low as 0.1 µg/ml steps (66). In 154 
these cases, a homogeneous strain could be inaccurately considered heteroresistant, and 155 
sometimes the same strain appeared as homogenous in one curve and heterogeneous in another 156 
(12).  157 
 A modified PAP assay comparing the area under the curve (PAP-AUC) of a given strain to 158 
that of a reference heteroresistant strain was used to determine S. aureus heteroresistance to 159 
vancomycin (67-81). The PAP-AUC ratios between test and control strain of <0.9, 0.9 to 1.3, 160 
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and >1.3 were considered indicative of vancomycin susceptible S. aureus, heterogeneous 161 
vancomycin intermediate S. aureus (hVISA), and vancomycin intermediate S. aureus (VISA), 162 
respectively (67, 72, 74, 76). Because this method relies on the vancomycin response of the S. 163 
aureus control strain, any instability in the antibiotic resistance of the control would cause 164 
significant changes in the results. The typical PAP method is time-consuming and labor 165 
intensive, and may not be suitable for clinical laboratories that screen hundreds of isolates for 166 
heteroresistance. A variation of PAP to screen clinical isolates for heteroresistance against 167 
glycopeptides used plates containing a single concentration of either vancomycin or teicoplanin 168 
(56, 68-70, 75, 82-84). However, comparative studies indicated that this method is not reliable 169 
for detecting heteroresistance (83, 85). 170 
 171 
Disc diffusion and Etest assays 172 
Disc diffusion (3, 14, 18, 55, 86-92) and Etest strips were used to detect heteroresistance as 173 
recommended for traditional in vitro susceptibility testing (6, 15, 18, 50, 63, 64, 66, 68, 71, 73, 174 
76, 80, 86, 88-91, 93-101). Special Etest strips were developed for glycopeptides resistance 175 
detection (GRD Etest) (69, 74, 75, 81, 102). These are double-sided strips where one side 176 
contains vancomycin and the other teicoplanin. As with PAP, lack of standard guidelines 177 
hampers detection of heteroresistance using Etest and disc diffusion assays. An obvious 178 
indication of heteroresistance is the appearance of distinct colonies growing within the clear zone 179 
of inhibition in the disc diffusion or Etest assays. However, many reports set cut-off 180 
concentrations or inhibition zone diameters to decide on the heterogeneity of the response of the 181 
bacterial population to antibiotics as discussed before, but such cut-off values cannot sufficiently 182 
describe the population-wide behaviour.  183 
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 184 
Additional methods to characterize heteroresistance 185 
Agar plates containing a linear gradient of antibiotic concentrations were used to determine the 186 
antibiotic susceptibility of clinical isolates and identify antibiotic-resistant cells within bacterial 187 
populations (103). Flow cytometry using a fluorescent penicillin derivative is another approach 188 
employed to assess heteroresistance in methicillin-resistant S. aureus (MRSA) compared to 189 
isolates with known heteroresistance (104). Other methods to characterize heteroresistant 190 
bacteria have included bacterial re-growth at later time points in time-kill assays after an initial 191 
significant growth reduction (9, 40), and increased MIC values of the same strain on prolonging 192 
the incubation time (27). Both methods allow time for proliferation of less abundant and more 193 
resistant members of the population. Also, uninterpretable and irreproducible MIC results in the 194 
form of ‘skipwells’ (wells exhibiting no growth although growth still occurs at higher 195 
concentrations of the antibiotic) could suggest heteroresistance, which was further confirmed by 196 
PAP in isolates of Enterobacter cloacae and Enterobacter aerogenes against polymyxin B (105). 197 
 198 
HETERORESISTANCE IN DIFFERENT BACTERIAL SPECIES 199 
Heteroresistance denotes the presence of subpopulations of bacterial cells in the same culture 200 
with higher levels of antibiotic resistance. Individual subpopulations of more resistant bacteria 201 
were often isolated, but their stability differed. Typically, after five to ten serial passages in 202 
antibiotic-free medium some highly resistant subpopulations reverted to the heterogeneous 203 
resistance phenotype displayed by their original population (3, 30, 40), whereas others retained 204 
their high-level resistance (6, 28). Most of the reported incidences of heteroresistance involve 205 
bactericidal antibiotics including β-lactams, glycopeptides, antimicrobial peptides, 206 
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fluoroquinolones, aminoglycosides, and the nitroimidazole antibiotic metronidazole that acts on 207 
anaerobic bacteria (Tables 1 and 2). No systematic comparisons of the response of 208 
heteroresistant bacteria to bacteriostatic versus bactericidal antibiotics have been reported, except 209 
for one study in Burkholderia cenocepacia (6) showing heteroresistance to different classes of 210 
bactericidal antibiotics and homogenous responses to bacteriostatic antibiotics. Two studies 211 
reported incidences of heteroresistance against bacteriostatic antibiotics. One of them involved S. 212 
aureus strains heteroresistant to fusidic acid (45), but PAP was performed using a narrow range 213 
of antibiotic concentrations in small increments. The other study reported Bordetella pertussis 214 
strains being heteroresistant to erythromycin (88), which appear as discrete colonies in the clear 215 
zones of inhibition after 7 days of incubation in Etest and disc diffusion assays. 216 
 Heteroresistance in Gram-positive bacteria was reported for S. aureus, as well as for other 217 
Staphylococci, Enterococci and Clostridium difficile. The earliest reports of heteroresistance in S. 218 
aureus were on the response to methicillin (3, 4), but this extended to other β-lactams, which 219 
accounted for the majority of research on heteroresistance until late 1990s (Table 1).  220 
Heteroresistance to vancomycin and other glycopeptides was first detected in Japanese 221 
vancomycin-resistant S. aureus (13). This also initiated a trend of PAP testing with a narrow 222 
range of antibiotic concentrations in very small increments, which were used to determine the 223 
clinical relevance and spread of vancomycin resistance in MRSA infections. However, 224 
controversial findings, originating from similar time range and geographical distribution, 225 
indicated that "heterogeneity" in response to vancomycin is common among S. aureus strains 226 
(47, 50, 61, 63, 70, 79, 95). Others reported that heteroresistance to vancomycin was not 227 
prevalent (51, 64, 72, 73, 80, 81, 102, 106). These studies promoted the assessment of 228 
heteroresistance in clinical laboratories as a standard procedure, but the results were conflicting 229 
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since different criteria to define heteroresistance were adopted and improper methods to detect 230 
heterogeneity were mostly used (discussed above under ‘Measuring Heteroresistance’). 231 
Fewer reports described heteroresistance in Gram-negative bacteria. Table 2 summarizes the 232 
incidences of heteroresistance in Pseudomonas aeruginosa, Klebsiella, Acinetobacter, and B. 233 
cenocepacia.  234 
Antibiotic resistance generally can be intrinsic or acquired (107), and the same applies to 235 
heteroresistance. Intrinsic heteroresistance occurs without pre-exposure to the antibiotic, but may 236 
also be acquired or induced after initial exposure to antibiotics. For example, repeated exposure 237 
of homogenously sensitive Staphylococci to methicillin resulted in mixed populations resembling 238 
the intrinsically heteroresistant strains (3). Similarly, B. cenocepacia displayed intrinsic 239 
heteroresistance to several bactericidal antibiotics including polymyxin B (6). However, acquired 240 
resistance after exposure to multiple rounds of selection in polymyxin B was shown for a B. 241 
cenocepacia hldA mutant possessing truncated lipopolysaccharide, which developed highly 242 
resistant subpopulations at polymyxin B levels not even tolerated by the most resistant members 243 
of the original population (108). A similar selection for MRSA involving step-wise exposure to 244 
vancomycin, led to acquired heteroresistance (109). Acquired heteroresistance may also originate 245 
from genetic events such as transposition (110, 111) or conjugation (112). The generated 246 
progenies include cells having different MIC due to differences in the number of copies of the 247 
inserted resistance genes or random disruption of genes involved in the bacterial response to 248 
antibiotics. 249 
Molecules besides antibiotics can also induce heteroresistance. For example, exogenous 250 
glycine led to heterogeneous response to methicillin in the highly homogeneous MRSA COL 251 
strain (31). The heterogeneous resistance phenotype in this case was decreased methicillin 252 
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resistance in subsets of the population, as increasing glycine concentration in the medium 253 
resulted in replacement of the D-alanyl-D-alanine peptidoglycan muropeptides with D-alanyl-254 
glycine muropeptides.  255 
Bacteria growing as biofilms are physiologically distinct from their planktonic counterparts 256 
and generally more resistant to antibiotics (113). Biofilms are populations of microorganisms 257 
that are concentrated at an interface (usually solid-liquid) on biotic or abiotic surfaces and 258 
typically surrounded by an extracellular polymeric matrix (113). Bacterial cells within a biofilm 259 
display a wide range of physiological states; these states arise from genotypic and phenotypic 260 
variations leading to distinct metabolic pathways, stress responses and other differences (114). 261 
Variation in levels of resistance across a bacterial population together with enhanced ability to 262 
form biofilm acted synergistically in P. aeruginosa infection (115). While biofilms occur in 263 
many infectious diseases, standard antimicrobial susceptibility testing procedures rely on 264 
planktonic cells. Thus, whether biofilms and the inherent variability among their populations 265 
contribute to the detection of heteroresistance remains to be explored. 266 
 267 
MECHANISMS OF HETERORESISTANCE  268 
Non-genetic individuality in bacterial populations has been observed in differentiation and cell 269 
division (116), chemotaxis (117), enzymatic activity (118), sporulation (119), stress responses, 270 
and antibiotic resistance (120-122). These variations can be attributed to genetic, epigenetic, and 271 
non-genetic mechanisms. Genetic mechanisms explain many cases of variation across a bacterial 272 
population since increased resistance may be due to mutations or gene duplications of key 273 
resistance genes or regulatory systems. Long-term infection could result in instability of bacterial 274 
genomic DNA potentially leading to heteroresistance. For example, mutations in gene products 275 
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having metronidazole nitroreductase activities, mainly oxygen-insensitive NADPH 276 
nitroreductase (RdxA) and NADPH flavin oxidoreductase (FrxA), occurred in H. pylori 277 
heteroresistant to metronidazole (21). Epigenetic variation across the bacterial population can 278 
also occur. In this case, one or more genes whose products are involved in resistance to 279 
antibiotics are differentially expressed among cells within a bacterial population. Other non-280 
genetic mechanisms involved in heteroresistance include chemicals in the bacterial milieu that 281 
may modulate the response to antibiotics across the bacterial population. For example, putrescine 282 
mediates heteroresistance of B. cenocepacia to multiple antibiotics (6), and glycine leads to 283 
heterogeneous response to methicillin in S. aureus (31). These mechanisms will be discussed 284 
below with more details specific to each antibiotic class. 285 
 286 
Heteroresistance to β-lactams 287 
Chambers et al. showed that increased production of PBP2a, encoded by mecA, was responsible 288 
for increased methicillin resistance of a subset of the population (27). However, further studies 289 
by the same group revealed that high levels of resistance require other factors acting within the 290 
autolysis pathway (123). Differences in regulation of autolysins in homogeneous vs. 291 
heterogeneous resistant strains were suggested (124). However, subsequent reports argued 292 
against the involvement of mecA (8, 34) and penicillinase (34) in methicillin heteroresistance. 293 
Regulatory systems contribute to heteroresistance. Inactivation of transcription regulators, such 294 
as Sar (125) and the Sigma-B operon (126) were other factors suggested to underlie 295 
heteroresistance in MRSA (127). Nevertheless, Sigma-B contributed to methicillin resistance but 296 
not heteroresistance in S. epidermidis; inactivation of the anti-sigma factor RsbW switched 297 
heteroresistance to homogeneous high-level resistance (128). Heteroresistance to homogeneous 298 
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high resistance selection (HeR-HoR selection) by oxacillin was associated with increased 299 
mutation rate and expression of mecA and SOS response lexA/recA gene regulators (129). 300 
Increased expression of the agr (accessory gene regulator) system during HeR-HoR selection 301 
was required to tightly modulate SOS-mediated mutation rates, which then leads to full 302 
expression of oxacillin homogeneous resistance in very heterogeneous clinical MRSA strains 303 
(130). The PBP1 protein played a role in SOS-mediated RecA activation and HeR-HoR selection 304 
(131). Conversely, a mutation in the less resistant cells of a heterogeneous population seemed to 305 
be responsible of their increased susceptibility. Single nucleotide polymorphism in the dacA 306 
(diadenylate cyclase) gene, which synthesizes the second messenger cyclic diadenosine 307 
monophosphate (c-di-AMP), was detected in the more sensitive cells. Thus, decreasing c-di-308 
AMP levels resulted in reduced autolysis, increased salt tolerance and reduced basal expression 309 
of the cell wall stress stimulon (132). Interestingly, the Eagle-type heteroresistance was 310 
explained based on reduced repression of mecA transcription and penicillin-binding protein 2' 311 
production at high concentration (128 µg/ml) of methicillin, which did not occur at lower 312 
concentrations (1 and 8 µg/ml). Deletion of mecI, the repressor of mecA, converted the Eagle-313 
type resistance to homogeneous high methicillin resistance (16). In Streptococcus pneumoniae, 314 
the penicillin binding protein PBP2x, but not PBP2b or PBP1a, from a heteroresistant strain 315 
conferred heteroresistance in a homogenous strain (133). Counterintuitively, PBP2x expression 316 
was not altered in the more resistant cells, but the expression of certain phosphate ABC 317 
transporter subunits (PstS, PstB, PstC and PhoU) was upregulated, which may represent a form 318 
of adaption to antibiotic stress (133). 319 
Heteroresistance to β-lactams occurs in several Gram-negative bacterial species. Increased 320 
cephalothinase activity of the more resistant subpopulation was reported for Enterobacter 321 
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cloacae, Citrobacter freundii, Proteus vulgaris, and Morganella morganii (28). The New-Delhi 322 
β-lactamase (NDM-1) conferred heteroresistance in Providencia rettgeri (134). Similarly, 323 
elevated expression of the β-lactamase gene in resistant subpopulation compared to the native 324 
populations was detected in Klebsiella pneumoniae heteroresistant to meropenem (40), and 325 
imipenem-heteroresistant A. baumannii (91). However, certain carbapenem-heteroresistant A. 326 
baumannii isolates were carbapenemase negative, suggesting that other factors are involved in 327 
the phenomenon (90). Differences in transcriptional levels may also underlie heteroresistance in 328 
P. aeruginosa to carbapenems; the resistant subpopulations, compared to native ones, had 329 
significantly increased transcription levels of the mexB and mexY genes whose protein products 330 
are involved in multidrug efflux, and decreased expression of the oprD gene encoding an outer 331 
membrane porin (57). Slower growth in β-lactam resistant subpopulations of A. baumannii may 332 
protect against antibiotic challenge (18). In Enterobacter species, mutation of ampD which is 333 
involved in the regulation of production of a class C β-lactamase, at rates as high as 10-4 to 10-6, 334 
resulted in a heterogeneous population of bacterial cells with differing levels of β-lactam 335 
resistance (135). Heteroresistance of invasive non-typeable H. influenzae to imipenem depended 336 
in part on the penicillin binding protein PBP3 encoded by ftsI, PBP4 encoded by dacB, or AcrAB 337 
efflux system; with a potential role of regulatory networks in the control of the heterogeneous 338 
expression of the resistance phenotype (35). In B. cenocepacia, an ornithine decarboxylase 339 
homologue and YceI, a small conserved protein, played a role in heteroresistance to ceftazidime 340 
(6). 341 
A model for heteroresistance was constructed by introducing into a sensitive Escherichia coli 342 
strain the blaCTX-M-14 gene encoding a cephalosporin hydrolase on a plasmid carrying the green 343 
fluorescent protein. This permitted to follow heteroresistant bacteria since a subset of the cells 344 
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expressed more hydrolase and hence exhibited higher level of resistance to ceftriaxone (136). 345 
Heteroresistance was followed on a single-cell level owing to the fusion with the green 346 
fluorescent protein. This study showed that cells with hydrolase overexpression formed the 347 
majority of the population upon increasing antibiotic concentrations due to decreased growth 348 
rates rather than selection for resistant cells (136). 349 
 350 
Heteroresistance to glycopeptides 351 
Heteroresistance to glycopeptides has not been directly linked to a particular mechanism. Some 352 
studies reported increased incidence of mutations of regulatory genes in the heteroresistant 353 
populations. For example, agr was dysfunctional in 58% of hVISA strains while in only 21% of 354 
MRSA strains (84); hence agr dysfunction seems advantageous to S. aureus clinical isolates 355 
toward the development of vancomycin heteroresistance (49, 137). Similarly, compared to 356 
vancomycin susceptible MRSA, 13 of 38 (34%) hVISA possessed at least 1 non-synonymous 357 
mutation: 6 in vraSR, 7 in walRK, and 2 in rpoB genes (138). 358 
Several mutations increase resistance to glycopeptides, but whether these are involved in 359 
population-wide variation in resistance is yet to be determined. Mutation of the vraS gene led to 360 
upregulation of the VraSR two-component system and conversion to the hVISA phenotype (38). 361 
Various mutations within the essential walKR two-component regulatory locus involved in 362 
control of cell wall metabolism conferred increased resistance to vancomycin and daptomycin 363 
among several VISA strains (139). Also, a mutation in the response regulator of the GraSR two-364 
component regulatory system could increase resistance of hVISA to VISA, suggesting this is a 365 
mechanism of increased resistance in general rather than of heteroresistance (140). The rpoB 366 
mutation but not graR mutation was involved in hVISA (62), while in S. aureus rpoB-mediated 367 
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resistance to vancomycin was accompanied by a thickened cell wall and reduced cell surface 368 
negative charge (141). Furthermore, cell wall thickening was proportional to increased resistance 369 
to glycopeptides in coagulase-negative Staphylococci (53, 142) and in S. aureus (143), and rapid 370 
cell wall turnover with increasing positive charges through dltA over-expression led to repulsion 371 
of vancomycin and daptomycin (137). The expression of atlE (encoding an autolysin with an 372 
adhesive function) also increased proportionally with the vancomycin concentration in the 373 
culture of S. epidermidis (142).  374 
Independent novel mutations in the vanR, vanS, vanH, vanA, vanX and vanY genes occurring 375 
upon continuous exposure to antibiotics can give rise to heteroresistance among vancomycin-376 
resistant Enterococci strains (15, 97). Subpopulations of Enterococcus faecalis with different 377 
surface charges, expressed as bimodal zeta potential distributions were reported (144), a 378 
phenotype that may lead to heteroresistance similar to Staphylococci. 379 
 380 
Heteroresistance to antimicrobial peptides 381 
The mechanism of colistin heteroresistance in A. baumannii was attributed to loss of 382 
lipopolysaccharide production in subpopulations displaying high-level of colistin resistance, 383 
which were selected by serial passages on colistin plates at increasing concentrations (145). Loss 384 
of lipopolysaccharide was caused by an insertion sequence inactivating lipid A biosynthesis 385 
genes lpxA and lpxC (146). In contrast, heteroresistance to polymyxin B in B. cenocepacia 386 
depends on differences in the level of secretion of putrescine and YceI being differentially 387 
expressed across the different subpopulations (6). Moreover, a periplasmic component of an 388 
ABC transporter involved in biosynthesis of hopanoids was overexpressed in the more resistant 389 
subpopulation exposed to polymyxin B (6). While the role of this transporter in heteroresistance 390 
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was not directly evaluated, hopanoids contribute to polymyxin B resistance in B. cenocepacia 391 
(147). 392 
 393 
Heteroresistance to fluoroquinolones 394 
Heterogeneity of Bartonella sp. to ciprofloxacin was linked to a natural mutation Ser-83 to Ala 395 
(E. coli numbering) in the quinolone-resistance-determining region of gyrA (96). Similarly, gyrA 396 
and gyrB mutations were associated with levofloxacin heteroresistance in H. pylori; three amino 397 
acid mutation sites (87, 91, and 143) were found in GyrA of levofloxacin-resistant strains and an 398 
A406G amino acid substitution in GyrB was only found once (21). Putrescine, and to a less 399 
extent YceI, contributed to heteroresistance of B. cenocepacia to norfloxacin where mutants 400 
unable to produce either of them showed more homogeneous response to norfloxacin (6). 401 
 402 
Heteroresistance to fosfomycin 403 
Heteroresistance to fosfomycin is predominant among S. pneumoniae isolates (44). The UDP-N-404 
acetylglucosamine enolpyruvyltransferase MurA1, which catalyzes the first step of 405 
peptidoglycan synthesis, contributes to heteroresistance against fosfomycin; however, this is not 406 
the only factor involved and potentially such heteroresistance is multifactorial (44). 407 
 408 
Heteroresistance to rifampicin 409 
The small protein YceI and, to a less extent putrescine produced by the antibiotic-responsive 410 
ornithine decarboxylase are involved in heteroresistance of B. cenocepacia to rifampicin (6). The 411 
deletion of genes encoding them individually showed less heterogeneous phenotype compared to 412 
the wild type strain. 413 
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 414 
CLINICAL SIGNIFICANCE OF HETERORESISTANCE 415 
While some reports question the clinical significance of heteroresistance (51, 63, 76, 148), others 416 
argue for deterioration in clinical outcomes due to heteroresistant bacteria (46, 50, 64, 71, 77, 78, 417 
149-152). Lack of a standard definition of heteroresistance may lead to misidentification of 418 
homogenous strains as heteroresistant hindering proper assessment of its clinical relevance. 419 
Heteroresistance may also be misinterpreted when only a single colony, picked from primary 420 
bacterial populations isolated from patients, is analyzed for its susceptibility to antibiotics (86). 421 
Heteroresistance was relevant in recurrent infections (46, 71), chronic infections (78), and 422 
infections with increased mortality rates (64, 77, 150, 151). Underlying mechanisms for these 423 
therapeutic failures could be antibiotic selection for the more resistant cells within the bacterial 424 
population and chemical communication of resistance, as described in more detail below. 425 
 426 
Selection for the more resistant cells in the population 427 
Therapeutic dosing of antibiotics without considering the highly resistant subpopulations of a 428 
heteroresistant isolate would select for the more resistant subpopulations. This is particularly the 429 
case when the majority of the population is sensitive to antibiotics while only a small subset, 430 
undetectable through criteria set for traditional in vitro antibiotic susceptibility testing, displays 431 
resistance above the clinical breakpoint (Fig. 1). In these situations, antibiotic therapy would lead 432 
to eradication of the more sensitive members of the bacterial population and their replacement by 433 
the more resistant cells. For example, colistin treatment of a patient with meningitis due to a 434 
colistin-heteroresistant A. baumannii resulted in selection of colistin-resistant derivatives (149). 435 
Moreover, A. baumannii isolates transitioned in vivo from susceptibility to full-resistance to 436 
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carbapenems, with heteroresistance as an intermediate stage due to administration of meropenem 437 
(90). Meropenem pressure can produce meropenem-heteroresistant subpopulations of A. 438 
baumannii that could be selected for by suboptimal therapeutic drug dosages, giving rise to 439 
highly resistant strains (39). Evidence of in vivo development of heteroresistance from antibiotic 440 
therapy was also seen in a patient with MRSA (98). Initial treatment with glycopeptides led to 441 
the development of heterogeneous glycopeptide resistance, which transformed to full resistance 442 
following daptomycin treatment. A similar switch from susceptibility to heteroresistance 443 
occurred in A. baumannii infections after prolonged exposure to imipenem (91). 444 
 445 
Chemical communication of antibiotic resistance 446 
Highly resistant subpopulations of heteroresistant bacteria could further complicate the clinical 447 
picture of polymicrobial infections by providing protection to more sensitive bacteria through 448 
chemical signals. For example, P. aeruginosa could be protected from the antimicrobial peptide 449 
polymyxin B by a highly resistant subpopulation of the heteroresistant cystic fibrosis pathogen B. 450 
cenocepacia (6). Simultaneous infection by both organisms is not uncommon since cystic 451 
fibrosis patients often have polymicrobial infection (153). The polyamine putrescine and the 452 
YceI protein, a small conserved protein with a lipocalin fold, mediated protection. These 453 
chemicals were released from B. cenocepacia in the presence of the antibiotic and resulted in 454 
survival of P. aeruginosa at a polymyxin B concentration equivalent to recommended 455 
therapeutic breakpoints at which P. aeruginosa should be killed in pure culture (6). Exposure to 456 
host derived putrescine and other polyamines led to a transient increase in resistance to 457 
antimicrobial peptides in the urogenital pathogen Neisseria gonorrhoeae (154), suggesting that 458 
communication of resistance mediated by polyamines is likely a general phenomenon. Putrescine 459 
  21 
protected the surface of bacteria from the initial binding of polymyxin B (6) and reduced 460 
antibiotic-induced oxidative stress (155), while YceI could bind and sequester polymyxin B thus 461 
potentially reducing its levels in the bacterial milieu (6). 462 
Indole is another chemical signal implicated in the communication of antibiotic resistance. 463 
More resistant E. coli mutants arising from continuous antibiotic treatment protected less 464 
resistant cells of the same population from norfloxacin and gentamicin (156). Such mutants 465 
could maintain same levels of indole production in the presence of antibiotic treatment, which 466 
could protect less resistant cells that produced lower concentration of indole under antibiotic 467 
stress. These mutants cannot be considered highly resistant as their MIC is around the MIC 468 
breakpoint for antibiotic sensitivity especially for norfloxacin, hence questioning their survival in 469 
vivo at therapeutic doses of antibiotics. Moreover, this E. coli bacterial population may not be 470 
truly heteroresistant owing to the lack of significant variation in concentrations tolerated by its 471 
members. Although indole production is not common among bacteria (157), indole produced by 472 
E. coli conferred antibiotic resistance to indole-negative Salmonella enterica serovar 473 
Typhimurium (158), demonstrating another example of chemical communication. Protection 474 
from antibiotics also occurred through antibiotic degrading enzymes. Protection of sensitive 475 
bacteria was mediated by beta-lactamases produced from resistant E. coli cells against beta-476 
lactamase sensitive agents as cefamandole, but not cefotaxime, cefoxitin or imipenem which are 477 
more resistant to beta-lactamases (43). 478 
 479 
CONCLUSIONS AND RECOMMENDATIONS 480 
Despite being recognized since 1947, heteroresistance is often used indiscriminately to describe 481 
observations unrelated to population-wide responses to antibiotics. Lack of standard test formats 482 
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and global guidelines for determining heteroresistance contribute to disagreements between 483 
outcomes of different methods and diverse results from different laboratories (69, 74, 75). Since 484 
heteroresistance could have serious implications in antimicrobial therapy, a standard operational 485 
definition and methods to assess its clinical importance are essential.  486 
We recommend defining heteroresistance as the population-wide variation of antibiotic 487 
resistance, where different subpopulations within an isolate exhibit varying susceptibilities to a 488 
particular antimicrobial agent. Concerning methods, PAP remains the gold standard for detecting 489 
heteroresistance by CFU counts. Turbidimetric PAP is also an acceptable alternative if antibiotic 490 
concentration increments are set at 2-fold; however, monitoring bacterial growth at time points 491 
earlier than 24 h (and after reaching the late log-phase/early stationary phase) may be advisable 492 
to watch for outgrowth of the more resistant subpopulation. Therefore, an isolate can be 493 
considered heteroresistant when the lowest antibiotic concentration giving maximum growth 494 
inhibition is greater than 8-fold higher than the highest non-inhibitory concentration. A 8-fold 495 
difference could be regarded as intermediate heteroresistance, while a smaller difference would 496 
denote homogenous response to the antibiotic. In homogeneous cultures, the entire population is 497 
usually inhibited over a narrow increment of antibiotic in standard MIC broth or agar dilution 498 
assay, with cases of intermediate growth before reaching maximal inhibition at only one 499 
antibiotic concentration increment above the highest non-inhibitory concentration. This general 500 
observation of homogeneous response to antibiotics has been documented by PAP assays in our 501 
recent study (6). Since 2-fold fluctuations in antibiotic sensitivity could normally occur, further 502 
increase in the transition from no inhibition to full inhibition by 2-fold relative to the 503 
homogeneous response was considered intermediate heteroresistance; greater differences (>8-504 
fold) indicated heteroresistance as previously shown (6). This is similar to results observed in 505 
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previous reports but with more standardization; for example, the concentration inhibiting the 506 
entire population in PAP assays was 8-fold higher than MIC values (which cannot detect the 507 
more resistant minority) as opposed to homogeneous bacteria where it is the same concentration 508 
or just 2-fold higher (41). Disc diffusion or Etest assays, where growth of discrete colonies 509 
within the clear zone of inhibition indicates heteroresistance, could be an alternative to PAP. 510 
These discrete colonies represent subpopulations growing at concentrations that are inhibitory to 511 
the rest of the bacterial population suggesting population-wide variation in resistance. Antibiotic 512 
diffusion methods may therefore speed up screening of clinical isolates, but cannot replace PAP 513 
assays. In the absence of specific recommendations to address heteroresistance from agencies 514 
concerned with antibiotic resistance such as CLSI, BSAC and others, we propose a workflow 515 
scheme and interpretation criteria based on standard antibiotic sensitivity testing recommended 516 
by the same agencies (Fig. 2). This scheme includes modifications in the read-out and existing 517 
standard assays for detection of population-wide variation in antibiotic resistance (Fig. 2). 518 
Having worldwide standard criteria to define and assess heteroresistance will facilitate assessing 519 
its prevalence, clinical relevance, and impact on healthcare. Consequently, effective therapeutic 520 
strategies should be explored to counteract heteroresistance, which may include testing 521 
synergistic combinations of antibiotics (159) and using antibiotic adjuvants inhibiting key 522 
pathways involved in antibiotic resistance in conjunction with frontline antibiotics (6). A 523 
standard definition of heteroresistance would also help elucidate its nature by determining 524 
whether common mechanisms exist among different bacteria and against different antibiotic 525 
classes, and finding new targets for its disruption.  526 
We urge global organizations concerned with antimicrobial resistance to advocate for 527 
harmonized recommendations and coordinate general consensus concerning heteroresistance. 528 
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We believe this is of utmost importance especially in clinical practice where currently thousands 529 
of clinical isolates are screened for heteroresistance, but with non-standardized methods that 530 
differ among laboratories, precluding obtaining a global picture of this problem. We anticipate 531 
that accurate and standardized detection of heteroresistance will translate to superior therapeutic 532 
outcomes based on improved identification of heteroresistant bacteria and optimized strategies to 533 
eradicate them. 534 
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Table 1: Cases of Heteroresistance in Gram-positive bacteria 1098 
Organism Antibiotic Method Comments Reference 
S. aureus 
(MRSA 
isolates) 
Methicillin PAP by CFU using 2-fold increments 
and presence of colonies in the 
inhibition zone of disc diffusion tests 
Cultures consisted of mixed 
populations; the majority of cells were 
sensitive with a minority showing 
resistance 
(3) 
S. aureus Cephalexin; 
Oxacillin 
PAP by CFU using 2-fold increments The population comprised cells with 
differing levels of resistance 
(4) 
S. aureus Cephalothin; 
Methicillin; 
Cephalexin 
PAP by CFU using 2-fold increments 
and presence of colonies in the 
inhibition zone of disc diffusion tests 
Decreasing proportion of resistant 
organisms with increasing antibiotic 
concentration. Improper criterion for 
heteroresistance in diffusion assay 
based on diameter 
(14) 
S. epidermidis 
and S. 
haemolyticus 
Methicillin PAP by CFU using 2-fold increments Only a minority of cells in a culture had 
significant resistance 
(26)  
S. aureus Nafcillin PAP by CFU using 2-fold increments 
and MICs at 48 h giving greater values 
than at 24 h 
Susceptible cells represent the vast 
majority with a very small number (1 in 
106 cells) of highly resistant cells 
(27) 
S. aureus Methicillin 
“Thermosensiti
ve”  
PAP by CFU using 2-fold increments Ability to grow in high concentrations 
of methicillin, at 30°C but not at 37°C. 
(19) 
S. aureus Methicillin PAP by CFU  (8, 30-34, 132) 
S. aureus Methicillin 
"Eagle-type"  
PAP by CFU using 2-fold increments Resistance to high concentrations of 
methicillin (64-512 µg/ml) and 
susceptibility to low concentrations (2-
16 µg/ml)  
(16) 
S. epidermidis Methicillin; 
Oxacillin 
PAP  (128) 
S. pneumoniae Penicillin Etest (complicated by zone of 
hemolysis), and PAP by CFU using 
very small increments of 0.1 µg/ml) 
Potential misidentification of 
heteroresistance 
(66) 
S. aureus Oxacillin   (7) 
S. aureus Cefazolin;  
Methicillin 
PAP by CFU using 2-fold increments Detected heteroresistant MRSA with 
low cefazolin MIC; genetically distinct 
from 1980s hetero-MRSA  
(37) 
S. aureus Methicillin Flow cytometry using Bocillin FL 
comparing with known heteroresistant 
MRSA as reference 
New method but not compared to other 
methods 
(104) 
S. aureus Methicillin;  
Oxacillin 
PAP and selection of high resistance by 
growing at subinhibitory concentration 
of Oxacillin  
Selection led to conversion from 
heteroresistant to homogeneous highly 
resistant 
(129) 
S. pneumoniae Penicillin PAP by CFU  (133) 
S. aureus Ceftaroline PAP by CFU The frequency of resistant 
subpopulations: 1 in 104-105 
(160) 
S. epidermidis Methicillin; 
Vancomycin; 
Teicoplanin 
PAP by CFU using 2-fold increments Isolates tested from recurrent infection 
in dialysis patients 
(46) 
S. aureus Methicillin; 
Vancomycin 
PAP by CFU (compared spread-plate to 
spotting of 10 µl techniques) 
Spotting reproduces the standard 
spread-plate while saving plates and 
time. 
(42) 
S. aureus Methicillin; 
Vancomycin 
PAP Argued against a major role of resistant 
subpopulations in persistence or relapse 
in bacteremia 
(51) 
S. aureus Vancomycin PAP using 1 µg/ml increments The first report of narrow increments in 
PAP was in 1997 using vancomycin 
(13, 47, 48, 140) 
S. aureus Vancomycin PAP 
Disc diffusion examining for satellitism 
Vancomycin heteroresistance is 
induced by β-lactams; sequential use of 
the 2 antibiotics may facilitate the 
emergence of glycopeptide resistance 
(87) 
S. aureus Vancomycin CFU on plates with 4 µg/ml 
Vancomycin  
Method is not reliable and may select 
for rather than detect heteroresistance  
(82, 85) 
Enterococcus 
faecium 
Vancomycin E-tests (growth in zone of inhibition)  (93) 
S. aureus Vancomycin PAP by CFU (narrow increments)  (12, 49, 52, 62, 
148) 
Coagulase 
negative 
Vancomycin,  
Teicoplanin 
PAP by CFU (narrow increments)  (53) 
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staphylococci 
S. aureus Vancomycin Etest  (95, 100) 
Staphylococcus 
spp. 
Vancomycin; 
Teicoplanin 
BHI Agar screening method with 4 or 6 
µg/ml; PAP (narrow increments) 
 (56) 
S. aureus Vancomycin 
and Teicoplanin 
BHI agar + 6 µg/ml Vancomycin, 
Mueller Hinton agar (MH) + 5 µg/ml 
Vancomycin and MH + 5 µg/ml 
Teicoplanin); Etest macromethod 
(using a 2 McFarland) 
Multi-Centre study of the methods: 
Intra- and inter-laboratory 
reproducibility varied between methods 
with poorest performance seen with 
screening plates compared to Etest 
(83) 
Enterococcus 
faecium 
Vancomycin  MIC by broth dilution; Etest (colonies 
in inhibition zone) 
High level of resistance (MIC>256 
µg/mL) by broth dilution but sensitivity 
by Etest (MIC=1.8 µg/ml ) 
(15) 
S. aureus Vancomycin Modified PAP by CFU on BHI agar 
+0.25, 0.5, 1, 1.5, 2, 4, 6 and 8 µg/ml 
Vancomycin. The area under the curve 
(AUC) was calculated  
Attempt to develop a new method that 
relies on comparison to a previously 
identified hVISA 
(67) 
S. capitis Vancomycin  PAP (1 µg/ml increments) and 
calculating (AUC test/AUC Mu3) 
ratios; Etest (colonies in inhibition 
zone); BHI agar +4 µg/ml Vancomycin 
Etest is more reliable and sensitive for 
detection of heteroresistance. 
Results suggest that PAP method 
should be revised and standardized 
(68) 
Enterococcus 
faecium  
Teicoplanin Etest  (97) 
S. aureus Glycopeptides Etest GRD strips, with one incorporated 
with nutrients to enhance growth of 
hGISA; BHI agar + 6 µg/ml 
Vancomycin; MH agar + 5 µg/ml 
Teicoplanin; PAP-AUC 
Etest GRD strip utilizing standard 
media and inocula, proved to be a 
simple and acceptable tool for detection 
of hGISA/GISA for clinical and 
epidemiologic purposes. 
Glycopeptide screening plates 
performed poorly.  
(69) 
S. aureus Vancomycin  PAP by CFU using 2-fold increments  (38) 
S. aureus Vancomycin PAP-AUC; Screening cascade: BHI 
agar +5 µg/ml teicoplanin then MET 
for positive isolates 
Suggests a screening cascade to 
substitute PAP-AUC since not suitable 
in clinical practice. 
(70) 
S. aureus Vancomycin  MET; PAP (narrow increments) 
 
Etest criteria were based on a cutoff 
concentration: MET readings ≥8 µg/ml 
for vancomycin and teicoplanin or ≥12 
µg/ml for teicoplanin only indicate 
hVISA 
(58) 
S. aureus Vancomycin  Etest; PAP-AUC compared to Mu3  (64, 71, 73, 76, 
161) 
S. aureus Vancomycin PAP-AUC  (72, 78, 79) 
S. aureus Vancomycin, 
but not 
Telavancin 
(bactericidal 
lipoglycopeptid
e)  
PAP (narrow increments) 
 
Telavancin was efficacious in 
infections caused by hVISA in a murine 
bacteraemia model 
(59) 
S. aureus Vancomycin PAP by CFU compared to Mu3 
(hVISA) and Mu50 (VISA) 
Included a reported homogeneous strain 
and not only a heterogeneous one as 
controls 
(60) 
S. aureus Vancomycin/ 
glycopeptides 
MET; PAP  (61, 77) 
S. aureus Vancomycin PAP-AUC; MET; GRD Etest; broth 
microdilution, BMD (MIC cutoff ≥ 2 
µg/ml); standard Vancomycin Etest 
(MIC cutoff ≥ 2 µg/ml): Methods 
comparison with PAP-AUC as standard  
The most cost-effective strategy was 
BMD as a standalone assay or in 
combination with PAP-AUC. GRD 
Etest remained an alternative, but a 
single cut-off value was used in all 
cases 
(74) 
S. aureus Vancomycin PAP/AUC; MET; GRD Etest; BHI 
agars + 3 or 4 µg/ml Vancomycin: 
Methods comparison with PAP-AUC as 
standard 
Both Etest screening methods have 
excellent negative predictive values, but 
positive results require confirmation. 
BHI+ 3 and 4 µg/ml screening agars 
provided precise identification of 
hVISA and VISA, respectively 
(75) 
S. aureus Vancomycin Broth microdilution; GRD Etest on 
4,210 clinical isolates from 43 U.S. 
centers; PAP-AUC for GRD-positive 
Low reproducibility between test 
methods. The overall prevalence of 
hVISA was low (0.3%) 
(102) 
S. aureus Vancomycin Broth microdilution; MET; Standard 
Etest on 220 clinical isolates (121 
MET identified 5.5% as  hVISA 
isolates; with higher percentage among 
(84) 
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MSSA, 99 MRSA) from bloodstream 
infections. 
PAP-AUC; BHI agar +4 µg/ml 
Vancomycin 
MRSA (9.1%) versus MSSA (2.5%) 
S. aureus Vancomycin PAP on 750 MRSA clinical strains 
isolated from Japan in 1990, before the 
introduction of injectable Vancomycin 
into clinical use in Japan in 1991 
Identified 5.1% as hVISA strains from 
19 hospitals. hVISA was present in 
Japanese hospitals before clinical 
introduction of vancomycin 
(138) 
S. aureus Vancomycin Etest; PAP-AUC on 288 MRSA 
isolates from a Connecticut Veterans 
Hospital 
Low prevalence of hVISA arguing 
against routine screening 
(80) 
S. aureus Vancomycin PAP on 268 MRSA isolates from 
Seoul, Republic of Korea 
37.7% were identified as hVISA. 
However, overall mortality was similar 
in hVISA and VSSA-infected patients 
(63) 
S. aureus Vancomycin GRD Etest; PAP-AUC on 43 MRSA 
isolates from Malaysia  
Two isolates were hVISA. (81) 
S. aureus 
MRSA 
Glycopeptides; 
Daptomycin 
Etest. In vivo development to heteroresistance (98) 
S. aureus Daptomycin PAP by CFU (narrow increments)  Despite using narrow increments, 
would be still heterogeneous if used 
with 2-fold increments 
(54) 
S. aureus Daptomycin PAP PAP demonstrated daptomycin 
heteroresistance among tested hVISA 
and VISA strains 
(162) 
Toxigenic 
Clostridium 
difficile  
Metronidazole Etest and disc diffusion (appearance of 
colonies in clear zone) 
Prolonged exposure to metronidazole 
can select for resistance in vitro. 
Routine disk diffusion assay (5 µg 
metronidazole disk) with primary fresh 
C. difficile isolates was recommended 
(89) 
C. difficile Metronidazole  Heteroresistance to metronidazole was 
detected (~24% of 110 isolates) 
(163) 
Staphylococcus Ciprofloxacin 
but not 
nalidixic acid  
PAP & MIC MIC for Ciprofloxacin of cells selected 
from plates with the highest 
concentration allowing growth was 
higher than that of the parental strains 
(29) 
S. pneumoniae Fosfomycin PAP (wide scale of increments higher 
than 2-fold) 
10 out of 11 strains tested displayed 
heteroresistance 
(44) 
S. aureus Fusidic acid PAP by CFU (narrow increments)  Cell populations have cells with 
different levels of resistance. More 
resistant subpopulations exhibited 
homogeneous resistance compared to 
their respective parental strains 
(45) 
BHI, Brain heart infusion; GRD Etest, glycopeptide resistance detection Etest; MET, Macro-Etest (referring to an Etest in which 1099 
higher inoculum sizes increase the probability of detection of more resistant members of the bacterial population); hGISA, 1100 
heterogeneous glycopeptides intermediate S. aureus; hVISA, heterogeneous vancomycin intermediate S. aureus; MSSA, 1101 
Methicillin-sensitive S. aureus; PAP-AUC, population analysis profiling-area under the curve method.  1102 
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Table 2: Cases of Heteroresistance in Gram-negative bacteria 1104 
Organism Antibiotic Method Comments Reference 
Type b H. 
influenzae 
Streptomycin PAP by CFU count (concentrations 
<10-1000 U/ml) 
Most of the culture was inhibited at 10 
units/ml. Few resistant cells survived 10-100 
U/ml and fewer at 1000 U/ml 
(2) 
Enterobacter 
aerogenes; E. coli; 
other 
Enterobacteria 
Cefamandole; 
Cefoxitin,; 
Carbenicillin; 
Nalidixic acid. 
PAP by CFU (2-fold increments)  This assay format was used to determine 
antibiotic resistance frequency 
(25) 
E. coli Cefamandole; 
Cefotaxime; 
Cefoxitin; 
Imipenem 
Turbidimetric PAP (2 fold increments 
or more) 
Co-culture assays showed protection of 
sensitive cells by β-lactamases produced 
from resistant cells from β-lactamase 
sensitive agents (cefamandole, but not 
cefotaxime, cefoxitin or imipenem) 
(43) 
8 species of 
Enterobacteriaceae 
Cefotaxime PAP: E. coli and Proteus mirabilis: 
homogeneous; Klebsiella oxytoca and 
Citrobacter koseri: less homogeneous; 
Enterobacter cloacae, Citrobacter 
freundii, Proteus vulgaris, and 
Morganella morganii: heterogeneous 
More resistant subpopulations from the 4 
heteroresistant species had a very high 
increase in cephalothinase activity compared 
to parental strains 
(28) 
P. aeruginosa, and 
7 strains from 5 
genera of 
Enterobacteriaceae 
Ciprofloxacin PAP and MIC MIC for Ciprofloxacin of cells selected from 
the plates with the highest concentration 
allowing growth was higher than that of the 
parental strains 
(29) 
Helicobacter 
pylori 
Metronidazole Etest and disc diffusion (small or large 
colonies were growing within the zone 
of inhibition) 
Risk of misinterpretations when antibiotic 
susceptibility testing is based on a single 
colony picked from the populations isolated 
from patients 
(86) 
A. baumannii Imipenem; 
Meropenem  
Etest (Colonies in the clear zone of 
inhibition) 
Warned that using carbapenems may lead to 
selection of resistant subpopulations 
subsequently causing dissemination of 
resistant strains and to therapeutic failure 
(94) 
A. baumannii Colistin PAP by CFU (narrow increments, but 
would still be heteroresistant if tested 
using 2-fold increments); Time kill 
curves (regrowth at late time point ~24 
h, after rapid early killing indicates 
heteroresistance) 
Subpopulations (<0.1% from 108 -109 
CFU/ml) grew in the presence of colistin 3 
to 10 µg/ml while the MIC of entire 
populations ranged from 0.25-2 µg/ml.  
Warned that recommended dosing is 
suboptimal for heteroresistant strains 
(9) 
P. aeruginosa  Imipenem; 
Meropenem 
Disc diffusion (colonies in inhibition 
zone); PAP by CFU: (narrow 
increments and low initial inoculum) 
Subpopulations growing at high 
concentration at frequencies 6.9 x 10-5 - 1.1 
x 10-7, suggest that these cells might not be 
detected by standard agar dilution MIC 
assay 
(55) 
Invasive 
nontypeable H. 
influenzae 
Imipenem PAP by CFU using 2-fold increments 
and Etest to determine MIC 
 (35) 
Enterobacter 
cloacae and A. 
baumannii 
Colistin Disk diffusion; Etest; agar dilution; 
broth microdilution 
 
Isosensitest agar was better than Mueller 
Hinton agar in detection of heteroresistance 
(11) 
A. baumannii-
calcoaceticus 
complex  
Colistin PAP by CFU using 2-fold increments Heteroresistance was defined by growth of 
colonies on plates containing 8 µg/ml of 
colistin, while the MIC=8 µg/ml by broth 
microdilution 
(36) 
P. aeruginosa  Carbapenems Agar dilution according to CLSI. 
Increments of 2 µg/ml for 
concentrations ranging from 2 to 32 
µg/ml and of 8 µg/ml from 32 to 64 
µg/ml  
Mutant subpopulations had at least 4-fold 
higher MIC than those of native cells for 
imipenem and meropenem 
(57) 
Bartonella sp. Ciprofloxacin Etest  (96) 
A. baumannii  Ampicillin/ 
Sulbactam 
Etest (incubation for ≥48 h)  Resistance could be induced after ≥48 h of 
antimicrobial exposure; hence 24 h 
incubation of test plates may not be enough 
to screen for heteroresistance 
(99) 
A. baumannii Carbapenem Disk-diffusion; Etest: colonies in clear 
zone of inhibition 
in vivo evolution of an antimicrobial profile 
from susceptibility to full-resistance to 
carbapenems, with heteroresistance as an 
intermediate stage 
(90) 
E. aerogenes Carbapenem  Etest Automated MicroScanWalkAway system (164) 
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failed to detect heteroresistance detected by 
Etest 
A. baumannii Meropenem PAP by CFU using 2-fold increments Suggests that A. baumannii isolates that are 
apparently meropenem susceptible by 
standard susceptibility testing may contain 
resistant subpopulations that could be 
selected for by suboptimal therapeutic drug 
dosages 
(39) 
K. pneumoniae Meropenem  MIC & PAP (2 fold increments); Time 
kill assays 
Re-growth of heteroresistant strains after 
initial killing phase 
(40) 
K. pneumonia Carbapenem Etest (colonies in inhibition zone); 
PAP. 
Low reproducibility of MIC led to 
investigation of heteroresistance 
(101) 
A. baumannii Imipenem Etest; disk diffusion (colonies in the 
inhibition zone) 
Switch from imipenem susceptibility to 
heteroresistance was more likely to occur in 
strains successively isolated from patients 
who had been exposed to imipenem (10.9 ± 
6.5 days exposure vs. 5.3 ± 4.8 days for 
controls) 
(91) 
Carbapenemase-
producing K. 
pneumoniae 
Colistin  PAP by CFU using 2-fold increments 
and MIC 
 (41) 
A. baumannii Cefepime 
 
PAP by CFU using 2-fold increments, 
Etest, and disc diffusion 
PAP of an isolate had 2 peaks of growth at 
different cefepime concentrations 
(18) 
A. baumannii Carbapenems Disc diffusion (colonies in zone of 
inhibition)  
Heteroresistance was referred to as 
phenotypic heterogeneous resistance 
(92) 
P. aeruginosa Polymyxin B PAP by CFU (PmB concentrations 
from 0 to 8 µg/ml)  
Isolates presenting subpopulations that 
exhibited growth at Polymyxin B 
concentrations ≥2 µg/ml were considered 
heteroresistant. Isolates containing 
subpopulations that grew at Polymyxin B 
concentrations at least twice higher than the 
original MIC but <2 µg/ml were 
considered heterogeneous 
(65) 
B. cenocepacia Polymyxin B; 
Norfloxacin; 
Rifampicin; 
Ceftazidime; 
Gentamicin;  
 
Etest; PAP by CFU and turbidimetric (2 
fold increments) 
Detailed comparison of population-wide 
response to bacteriostatic vs. bactericidal 
antibiotics showing heteroresistance only 
against bactericidal agents. Criteria adopted 
for interpretation of heteroresistance are 
similar to those recommended here 
(6) 
E. cloacae; E. 
aerogenes 
Polymyxin B PAP Multiple skip wells were observed in 
polymyxin susceptibility testing of 
Enterobacter species leading to 
uninterpretable results 
(105) 
H. pylori Levofloxacin; 
Clarithromycin; 
Metronidazole 
MIC by Etest and agar dilution for 19 
pairs of clinical isolates. Each pair was 
isolated from the same patient  
Heteroresistance was reported when pairs 
showed difference in resistance in 5, 1 and 
19 cases for levofloxacin, clarithromycin 
and metronidazole respectively. 
(21) 
Providencia 
rettgeri 
Carbapenems PAP by CFU  (134) 
Bordetella 
pertussis 
Erythromycin Disc diffusion and Etest Heteroresistance was not detected except 
after 7 days of incubation when colonies 
appeared in clear zone. Degradation of 
erythromycin from the disc on long 
incubation was ruled out 
(88) 
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Figure legends 1109 
 1110 
 1111 
FIG. 1. Heteroresistant vs. homogenous response to antibiotics. Dotted lines represent 1112 
breakpoints for resistance. Homogenous bacterial cultures (A-C) can either be A, 1113 
susceptible, B, of intermediate susceptibility, or C, resistant to an antibiotic according to 1114 
traditional in vitro susceptibility testing. Heteroresistant bacteria (D-F) may be: D, 1115 
completely susceptible to an antibiotic, whereby the different subpopulations respond to 1116 
antibiotic concentrations extending below the breakpoints. This form is less likely to be 1117 
detected and is probably the least clinically important (unless the least responsive 1118 
subpopulations develop resistance to the antibiotic). E, the more classical form of 1119 
heteroresistance in which the majority of the bacterial population is susceptible to an 1120 
antibiotic with a highly resistant minority. Antibiotic treatment guided by the traditional 1121 
susceptibility testing breakpoints would select for the resistant subpopulation, leading to 1122 
therapeutic failure. F, the entire bacterial population, including the least resistant 1123 
subpopulations, is resistant to the antibiotic. Chemical communication of antibiotic 1124 
resistance from the more resistant members of the population protecting less resistant 1125 
bacteria is the major concern of such bacterial populations. 1126 
 1127 
FIG. 2. Recommended scheme for determination of heteroresistance and 1128 
interpretation criteria. Disc diffusion assays should be performed according to 1129 
standardized procedures for antimicrobial susceptibility testing as recommended by 1130 
agencies such as CLSI or BSAC. These procedures may be applied to Etest assays while 1131 
taking into consideration the manufacturer guidelines. PAP by CFU counts should be 1132 
performed by plating aliquots of 10-fold serially diluted bacterial cultures on antibiotic-1133 
containing agar plates. Agar plate preparation should follow standardized guidelines used 1134 
for MIC by agar dilution assays. Turbidimetric PAP should follow the standard MIC by 1135 
broth dilution technique, with the exception of turbidimetric quantification of bacterial 1136 
growth at each antibiotic concentration.  1137 
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Figure 2 1145 
